Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan

BACKGROUND: The CARD trial was conducted in patients with metastatic castration-resistant prostate cancer (mCRPC) who had received docetaxel and experienced disease progression within 1 year on an androgen receptor-axis-targeted therapy (ARAT). Subsequent treatment with cabazitaxel had improved clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Hideyasu, Matsubara, Nobuaki, Kazama, Hirotaka, Seto, Takeshi, Sunaga, Yoshinori, Suzuki, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262372/
https://www.ncbi.nlm.nih.gov/pubmed/37308888
http://dx.doi.org/10.1186/s12885-023-10998-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262372/
https://www.ncbi.nlm.nih.gov/pubmed/37308888
http://dx.doi.org/10.1186/s12885-023-10998-w

Ejemplares similares